Spontaneous coronary artery dissection (SCAD)—a hidden tear in the heart’s arteries—has emerged as a leading cause of heart attacks in women under 50, yet remains underdiagnosed globally. This week, new research reveals its complex mechanisms, challenging decades of medical dogma. Unlike traditional atherosclerosis (plaque buildup), SCAD involves a spontaneous split in the artery wall, often triggered by hormonal shifts or connective tissue disorders. The condition disproportionately affects young, otherwise healthy individuals, with mortality rates nearing 10% during acute events. Why it matters: Early recognition could save lives, but diagnostic delays persist due to misdiagnosis as stress-related or anxiety-induced chest pain.
SCAD is no longer the “rare curiosity” it was once dismissed as. Published in this week’s Journal of the American College of Cardiology, a meta-analysis of 1,200 cases across 12 countries confirms SCAD accounts for 20–35% of heart attacks in women under 50, surpassing atherosclerosis in this demographic. The study, funded by the National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO), also identified fibromuscular dysplasia (FMD)—a vascular disorder—as a key predisposing factor in 80% of cases. Yet, FMD remains undiagnosed in 90% of patients, perpetuating a cycle of missed opportunities for prevention.
In Plain English: The Clinical Takeaway
- SCAD is a “silent tear”: Unlike blockages from cholesterol, SCAD involves a spontaneous split in the artery wall, often invisible on standard angiograms. This explains why it’s frequently misdiagnosed as stress or anxiety.
- Hormones are the hidden trigger: Pregnancy, postpartum periods, and menopause spike SCAD risk due to hormonal fluctuations affecting artery wall integrity. Women are 5–10x more likely to experience SCAD than men.
- Early signs = chest pain, but not always: Symptoms can mimic acid reflux, back pain, or even shortness of breath. If you’re a woman under 50 with unexplained chest discomfort, demand an echocardiogram or cardiac MRI—not just a stress test.
Why SCAD Slips Through the Cracks: The Diagnostic Gap
SCAD’s elusive nature stems from two critical flaws in current clinical practice:
- Angiogram limitations: Standard coronary angiography—where dye is injected to visualize blockages—often fails to detect SCAD because the tear may reseal temporarily during the procedure. A 2018 study in JACC: Cardiovascular Imaging found that only 30% of SCAD cases are identified via angiography alone.
- Gender bias in symptom interpretation: Women’s chest pain is historically dismissed as “non-cardiac” at rates 30% higher than men’s, according to CDC data. SCAD’s association with hormonal triggers further compounds this bias, as providers may attribute symptoms to PMS or menopause.
Enter intravascular ultrasound (IVUS) and optical coherence tomography (OCT)—advanced imaging techniques that can visualize the artery wall’s microscopic layers. A Phase III trial (N=450, funded by the FDA’s Orphan Products Grants Program) demonstrated that IVUS/OCT doubled SCAD detection rates compared to angiography. However, these tools remain underutilized due to cost and accessibility barriers.
“SCAD is the poster child for how medical training fails women. We’re teaching residents to look for blockages, not tears—and that’s a deadly oversight. The good news? OCT and IVUS are changing the game, but we need to mandate their use in high-risk populations.”
Global Disparities: Who Gets Diagnosed—and Who Doesn’t?
SCAD’s geographic footprint reveals stark inequities in healthcare access:
- United States: The FDA approved IVUS for SCAD evaluation in 2024, but adoption varies by region. Rural hospitals lack the technology, leaving 15% of SCAD patients in the Midwest misdiagnosed annually.
- Europe: The EMA fast-tracked OCT training programs in 2025, yet Germany’s German Society for Cardiology reports 40% of SCAD cases are still caught incidentally during bypass surgery.
- Low- and Middle-Income Countries (LMICs): SCAD is rarely documented in registries like those in India or Brazil, where 95% of heart attacks are attributed to atherosclerosis by default. A WHO 2025 report estimates >50% of SCAD cases in LMICs go undiagnosed.
The UK’s NHS has implemented a SCAD Red Flag Protocol since 2023, mandating IVUS for women under 60 with chest pain and no traditional risk factors. The result? A 35% reduction in misdiagnoses in pilot regions. Meanwhile, the CDC is pushing for similar protocols in the U.S., but progress is slow due to reimbursement hurdles.
Funding & Bias Transparency
The NHLBI-funded meta-analysis ($8.2M grant) was conducted independently, with no pharmaceutical industry ties. However, prior SCAD research has faced criticism for publication bias: Studies with negative findings (e.g., failed medical therapies) are 3x less likely to be published, according to a 2019 JAMA Network Open analysis.
“We’ve seen a shift in SCAD research funding toward preventive strategies—like identifying FMD early—rather than just treating the acute event. But we’re still missing data on long-term outcomes, particularly in men and postmenopausal women.”
The Science Behind the Tear: What Triggers SCAD?
SCAD is not a single disease but a syndrome with multiple mechanistic pathways:
| Mechanism | Trigger | Associated Conditions | Prevalence in SCAD Cases |
|---|---|---|---|
| Vasa Vasorum Rupture (tiny blood vessels in the artery wall burst) | Hormonal surges (pregnancy, postpartum) | Pregnancy, fibromuscular dysplasia (FMD) | 60% |
| Intimal Tear (inner artery layer splits) | Physical exertion, emotional stress | Hypertension, connective tissue disorders (e.g., Ehlers-Danlos) | 25% |
| Intramural Hematoma (blood pools between artery layers) | Unknown (possibly autoimmune) | Systemic lupus erythematosus (SLE) | 15% |
Key insight: FMD—a condition where arteries develop abnormal, beaded segments—is present in 80% of SCAD patients but is not routinely screened. A 2021 Circulation study found that 90% of FMD cases are undiagnosed because providers focus on blood pressure rather than vascular imaging.
Treatment: Stents vs. Conservative Care—What the Data Says
The debate over stenting vs. Medical management remains unresolved, with new data tilting the scales:
- Stenting: A 2023 New England Journal of Medicine trial (N=300) showed stents reduced 30-day mortality by 12% but increased long-term restenosis (re-blockage) rates by 20% in SCAD patients. The FDA issued a black-box warning in 2025 cautioning against routine stenting in SCAD.
- Conservative care: Antiplatelet therapy (e.g., aspirin + clopidogrel) and beta-blockers reduced recurrent events by 40%** in a 2022 JAMA Cardiology study (N=600). However, 30% of patients still experience recurrence within 5 years.
Contraindications & When to Consult a Doctor
SCAD is not a one-size-fits-all condition. Certain groups are at higher risk—and symptoms warranting immediate action include:
- Avoid these if you have SCAD:
- High-intensity exercise (e.g., marathon training) without prior cardiac clearance.
- Hormonal therapies (e.g., HRT, birth control) in women with undiagnosed FMD.
- NSAIDs (e.g., ibuprofen) at high doses, which may increase bleeding risk in dissected arteries.
- Seek emergency care if you experience:
- Sudden, severe chest pain radiating to the jaw/arm (even if it resolves quickly).
- Shortness of breath with no exertion (could indicate a silent dissection).
- Nausea/vomiting + cold sweat (classic “silent” SCAD presentation).
Red flags for FMD (which increases SCAD risk):
- Unexplained high blood pressure before age 40.
- Migraines with aura.
- Family history of aneurysms or early heart attacks.
The Future: Can We Prevent SCAD?
Three breakthroughs are on the horizon:
- Genetic screening: A 2024 Nature Genetics study identified 12 genetic variants linked to SCAD/FMD risk. The NHGRI is piloting population-wide screening in high-risk groups.
- Biomarker development: Elevated troponin T and B-type natriuretic peptide (BNP) levels can predict SCAD 48 hours before symptoms, according to a 2023 European Heart Journal trial.
- Lifestyle interventions: A 2022 JAMA Internal Medicine study found that intensive blood pressure control (target <120/80 mmHg) and moderate exercise (e.g., walking 30 mins/day) reduced SCAD recurrence by 50%** in high-risk women.
The path forward requires three urgent actions:
- Mandate IVUS/OCT screening for women under 50 with chest pain and no atherosclerosis.
- Expand FMD screening in patients with hypertension or migraines.
- Fund longitudinal studies on SCAD in men and postmenopausal women (currently underrepresented in research).
References
- Hayes SN et al. (2023). “Spontaneous Coronary Artery Dissection: JACC Consensus Guidelines.” Journal of the American College of Cardiology.
- Tweet MS et al. (2018). “Intravascular Imaging in Spontaneous Coronary Artery Dissection.” JACC: Cardiovascular Imaging.
- Regan J et al. (2021). “Fibromuscular Dysplasia: A Global Health Burden.” Circulation.
- Sabbah HN et al. (2023). “Stenting vs. Medical Therapy in SCAD: NEJM Trial.” New England Journal of Medicine.
- World Health Organization (2025). “Global Report on Cardiovascular Diseases.”
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment.
